AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01018459
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline placebo control delivered via intramuscular injection into the deltoid muscle.
Trial: NCT02165111
Drug: sterile saline solution
RxNorm normalized name: Blairex Sterile Saline Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01440946
Drug: rFIXFc
RxNorm normalized name: rFIXFc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vials of rFIXFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
Trial: NCT03594591
Drug: Antidiabetic treatment by usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation of changes in the microcirculation after optimization of antidiabetic therapy by usual care.
Trial: NCT01211275
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.
Trial: NCT00101101
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
Trial: NCT00101101
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
Trial: NCT04519658
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets by mouth once daily
Trial: NCT00799149
Drug: Gabapentin, Etoricoxib, Sugar pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Sugar pill) or gabapentin (1200 mg) or etoricoxib (120 mg) administered 30-90 min before the patient entered the operating room with a sip of water. Subsequent doses of the oral study drugs were administered on the mornings (08H00) of the first, second, and third postoperative days. .
Trial: NCT01357993
Drug: JNS001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mg, 27 mg and 36 mg tablets (18-72 mg/day) once daily for 48 weeks
Trial: NCT01934634
Drug: LCL161
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCL161 (tablets): 300, 600, 1200, or 1800 mg once a week (Day 1, 8, 15) for 3 weeks, every 28 days
Trial: NCT01848990
Drug: Commercial Hylenex® recombinant (hyaluronidase human injection)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02136875
Drug: Self-administered prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An Acute Exacerbation of COPD (AECOPD) is defined as a sustained worsening of dyspnea, cough or sputum production leading to an increase in the use of maintenance medication and/or supplementation with additional medication. In addition, exacerbations should be defined as either purulent or non-purulent.~Standing prescriptions for exacerbation:~1) Purulent exacerbation - Antibiotic: Avelox 400 mg daily for 5 days. 2a) Mild to moderate exacerbation - Combination therapy (SFP - Advair) to be increased as follows: If regular treatment is Advair 250/50 BID then dose should be increased to Advair 500/100 BID for 10 days; if regular treatment is Advair 500/50 BID then increase to Advair 1000/100 BID for 10 days.~2b) Severe exacerbation - Prednisone (oral): 40 mg once daily for 7-10 days
Trial: NCT00647621
Drug: Extended Phenytoin Sodium Capsules 100 mg
RxNorm normalized name: phenytoin sodium Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
Trial: NCT00647621
Drug: Dilantin® Kapseals® 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
Trial: NCT00650039
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, placebo BID by mouth on Days 2 to 5.
Trial: NCT00650039
Drug: valdecoxib
RxNorm normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg once daily (QD) by mouth on Days 2 to 5.
Trial: NCT00650039
Drug: valdecoxib
RxNorm normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg twice daily (BID) by mouth on Days 2 to 5.
Trial: NCT02423265
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo: up-titration after 1 week
Trial: NCT01486017
Drug: ASP015K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00917813
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1 - Physiological saline IV on Days 1, 8, and 15; Cohort 2 - Physiological saline IV on Days 1, 8, and 15; Cohort 3 - Physiological saline IV on Days 1, 8, and 15
Trial: NCT02379585
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
Trial: NCT02379585
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
Trial: NCT00963729
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00963729
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02447991
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of the study.
Trial: NCT01242904
Drug: bimodal solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mL of 30% glucose infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
Trial: NCT02932397
Drug: Intravenous dose of 0.05 mL/kg of saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04465175
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (2.5 ml/kg) infusion over one hour
Trial: NCT00568308
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo
Trial: NCT04346615
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Q8h for 14 days
Trial: NCT00002604
Drug: chemosensitization/potentiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03475160
Drug: Placebo vaginal suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vaginal suppositories. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
Trial: NCT00194012
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addressed in arm description.
Trial: NCT00218062
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00864500
Drug: Clobex TM 0.05% Lotion, single exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B:Active Comparator Subjects received Galderma Laboratories, L.P. formulated products
Trial: NCT01326780
Drug: 1.2% JNJ 10229570-AAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks
Trial: NCT01326780
Drug: 2.4% JNJ 10229570-AAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks
Trial: NCT01326780
Drug: 3.6% JNJ 10229570-AAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks
Trial: NCT00274716
Drug: MK0736
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00274716
Drug: MK0916
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00274716
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04031885
Drug: Standard Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy of physician's choice administered according to product label.
Trial: NCT01648777
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Isotonic NaCl solution (9°/00) solution: for the intravenous bolus of 10 ml~* Isotonic NaCl solution (9°/00) solution, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00
Trial: NCT00854087
Drug: Fuzheng Huayu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will be taking 2 tablets three times a day for 48 weeks.
Trial: NCT00854087
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will be taking 2 tablets three times a day for 48 weeks.
Trial: NCT00145509
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast-dissolving tablet; twice daily (BID) sublingually for 40 weeks
Trial: NCT02922452
Drug: Dilitazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose BMS-986141 and Multiple doses of Dilitazem
Trial: NCT01341184
Drug: TMC207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC207 400 mg orally on days 1 and 29
Trial: NCT00394966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
Trial: NCT03354429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo arm: Day 1, loading dose of placebo followed by placebo daily maintenance dose until Day 30.
Trial: NCT02285985
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets: 5mg
Trial: NCT04537806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as IV infusion.
Trial: NCT02477020
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-063 matching-placebo tablet.
Trial: NCT02845271
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solvent for parenteral use~Route of administration: intraarticular
Trial: NCT02845271
Drug: GZ389988
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:suspension for injection~Route of administration: intraarticular
Trial: NCT02845271
Drug: acetaminophen or paracetamol
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT02845271
Drug: fixed combination of paracetamol + codeine
RxNorm normalized name: codeine and paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Trial: NCT02285751
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03536728
Drug: AMXT1501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 40 mg or 200 mg (free base content) enterically-coated capsules
Trial: NCT02566759
Drug: TAK-831 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-831 placebo-matching oral suspension.
Trial: NCT01061060
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01034397
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv every 4 weeks for 24 weeks
Trial: NCT01034397
Drug: non-biological DMARDs
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: stable dose at investigator's prescription
Trial: NCT00963664
Drug: lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lovastatin tablets, oral administration, daily dose 1.5 mg/kg, divided into three or four essentially equal doses with meals
Trial: NCT04480710
Drug: CRV431 75mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 75mg softgel capsule
Trial: NCT04480710
Drug: Placebo (1 softgel)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x placebo softgel capsule
Trial: NCT04480710
Drug: CRV431 225mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 75mg softgel capsule
Trial: NCT02205892
Drug: Placebo vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are supposed to apply their control vehicle cream two times per day to the other side of their face for 4 weeks. Application side is randomly determined.
Trial: NCT00004026
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02942654
Drug: LY900014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (SC)
Trial: NCT01777945
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants received capecitabine according to individualized physician-prescribed regimen.
Trial: NCT03598751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL
Trial: NCT00238459
Drug: Patients elected to take licensed drugs. The vaccine was not provided for evaluation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Note:In August 2007 we were notified by the manufacturer that the experimental vaccine was no longer being made and would no longer be available for this study. Too few participants have received the vaccine or placebo to conclude anything about potential efficacy
Trial: NCT00238459
Drug: multiple licensed antiretroviral drugs; not randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03067376
Drug: [14C]-CORT125134
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03677297
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Test sites were treated with access flap surgery and 1.2% Rosuvastatin gel
Trial: NCT04233814
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo is micronized lactose powder administered by inhalation through a dry powder inhaler.
Trial: NCT00399399
Drug: azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00399399
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01406015
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg once daily for 6 weeks.
Trial: NCT01406015
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching spironolactone once daily for 6 weeks.
Trial: NCT01896583
Drug: ASP7147
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg, tablet, twice per day for 4 weeks oral
Trial: NCT01896583
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03652467
Drug: Conventional TACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemoembolization drugs are injected through hepatic artery.
Trial: NCT00982189
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants randomized to take pravastatin (active) or matching placebo pill once daily
Trial: NCT02074735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ingredient matching the active comparator in appearance
Trial: NCT03669081
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac was administered intravenously: 30 mg in the operating room, and 15 mg every 6 hours for 7 doses post-operatively.
Trial: NCT03669081
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule was administered orally 30 minutes prior to operation.
Trial: NCT00578773
Drug: Moxidex otic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
Trial: NCT01337258
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Men taking placebo daily
Trial: NCT01789216
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01732913
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally twice daily
Trial: NCT00210652
Drug: RWJ 333369:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-Label Extension: One 250mg tablet twice daily up to a total of 1200mg/day up until RWJ-33369 is available by prescription or study is terminated by sponsor
Trial: NCT02637934
Drug: [18F]FluorThanatrace
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01424488
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthetised patients will receive a single intubation dose of succinylcholine (1.0 mg/kg) and maintenance bolus dose of pipecuronium (0.08 mg/kg) to maintain the level of neuromuscular blockade at reappearance of T2. 3,0 ml of saline (placebo) is to be administered as an intravenous bolus dose at the level of neuromuscular blockade of reappearance of T2 (moderate blockade) by means of TOF-Watch SX after the last dose of pipecuronium according to randomization
Trial: NCT00239031
Drug: Enteric-Coated Mycophenolate Sodium
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-Coated Mycophenolate Sodium
Trial: NCT01494233
Drug: 250 mg LX1033 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg LX1033 tablets administered orally
Trial: NCT01494233
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet administered orally
Trial: NCT02550652
Drug: Mycophenolate Mofetil/Mycophenolic Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF/MPA will be administered as per schedule specified in the respective arm.
Trial: NCT03001895
Drug: 18F-DCFPyL PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F-DCFPyL PET/CT
Trial: NCT01337349
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar Pill 400mg taken orally three times a day for 6 months
Trial: NCT00659503
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT05303688
Drug: iv dexketoprofen trometamol (Arveles 50mg/2mL; UFSA, İstanbul, Turkey)
RxNorm normalized name: dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The primary predictor variable was preventive analgesia group. Patients were randomly divided in two groups. 50 mg iv dexketoprofen trometamol (Arveles 50mg/2mL; UFSA, İstanbul, Turkey) were administrated 30 minutes before incision in the treatment group (dexketoprofen trometamol n= 15
Trial: NCT05303688
Drug: Steril Salin (control)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 minutes before incision in the treatment group (dexketoprofen trometamol n= 15) and iv sterile saline were administrated 30 minutes before incision in the placebo group (saline n= 15).
Trial: NCT00559676
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00559676
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00559676
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04329494
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given via PIPAC
Trial: NCT04329494
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04380207
Drug: QPX7728
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antibiotic